FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare
Syndicate content

Diabetes news from FierceBioResearcher

News

Fat cell research points to new approach on obesity

Swedish researchers have concluded that the number of fat cells present in the body is a constant, remaining unchanged regardless of how much a person weighs or gains. Every year about 10 percent of Read more...
Tags: obesity   Diabetes  

Merck KGaA budgets $1.58B for drug R&D

With about 40 drug development projects in the pipeline, Germany's Merck KGaA says it will spend about €1 billion ($1.58 billion) on drug research this year. That R&D budget represents Read more...
Tags: Merck   Diabetes   Cancer  

Developers, geneticists brainstorm diabetes therapies

What do you get when you mix 20 drug developers active in the diabetes field with a room full of geneticists? Hopefully, a new generation of therapies that pinpoint subsets of the disease, each with Read more...

FDA mulls tougher standards on diabetes research

The FDA is taking a look at a fresh set of standards that demand new tests to determine if diabetes drugs elevate heart risks. Safety advocates sounded approving after seeing the FDA draft guidance Read more...
Tags: Diabetes   FDA  

Resveratrol shows promise as diabetes treatment

Scientists have unveiled yet another study on the potential of resveratrol. The chemical, which is found in red wine as Read more...

Enzyme discovery offers new direction in diabetes

A team of Australian scientists has found an enzyme in diabetics that prevents them from producing insulin. The researchers say that they intend to start working with drug developers to block Read more...

New hope for cross-species transplantation

Experiments using genetically-engineered pigs to make them compatible with the human immune system are raising expectations about the prospects of cross-species transplantation as an option for Read more...

Genetically modified cows to produce cheap insulin

Scientists working for Bio Sidus in Argentina have developed a genetically modified cow that can produce insulin in its milk. The company says the four cloned calves will start producing the insulin-rich milk when they reach maturity. To clone the cows, scientists insert a human gene into an embryo, which is then implanted in the mother. The insulin is later extracted from the milk. Bio Sidus said that the procedure can be used to develop insulin for 30 percent less than current methods …

Read more...
Tags: insulin   cloning   embryo   Diabetes  

New source on metabolic disorders

Bioengineering researchers at UC San Diego have painstakingly assembled a virtual human metabolic network that will give researchers a new way to hunt for better treatments for hundreds of human metabolic disorders--from diabetes to high levels …

Read more...
Tags: genome   Diabetes  

Insulin delivered in tiny carbohydrate shells

Taiwanese researchers have developed a new method for providing insulin to diabetics. Instead of injecting insulin, a standard delivery method, they developed tiny spheres made from shrimp cells that could survive the acid in the stomach and would pass through the small intestine, delivering the insulin into the blood. The process was tested successfully on rats. The research indicates that the current process requires a large amount of insulin. Advocates for diabetics said they would …

Read more...
Tags: Diabetes  

Press Releases

PRESS RELEASE: AtheroGenics Says Stops Highest Dose of Drug in Diabetes Trial

AtheroGenics Says Stops Highest Dose of Drug in Diabetes Trial ATLANTA, GA -- Nov 9, 2007 -- AtheroGenics, today announced that after discussions with the U.S. Food and Drug Administration (FDA), Read more...

PRESS RELEASE: Isis Adds New Drug to Its Development Pipeline: ISIS 388626

Isis Adds New Drug to Its Development Pipeline: ISIS 388626 Targeting SGLT2 for the Treatment of Type 2 Diabetes CARLSBAD, Calif., Oct. 18 -- Isis Pharmaceuticals, Inc. today announced that it has Read more...

PRESS RELEASE: Eli Lilly and Company in $494 Million Deal for Diabetes Drug

Eli Lilly and Company in $494 Million Deal for Diabetes Drug ROCKVILLE, Md., and INDIANAPOLIS, Oct. 18 -- Eli Lilly and Company and MacroGenics, Inc. today announced that the two companies have Read more...

PRESS RELEASE: Exelixis Diabetic Nephropathy Drug Trial Fails Goal

Exelixis Diabetic Nephropathy Drug Trial Fails Goal SOUTH SAN FRANCISCO, Calif., Oct. 16 -- Exelixis announced that a recently completed phase 2 trial of XL784 did not meet its primary endpoint of Read more...

Get more Diabetes coverage at: